FDA Approves Amgen & AstraZeneca’s Drug for Severe Sinus Condition in Teens and Adults
The U.S. Food and Drug Administration (FDA) has expanded approval for Tezspire (tezepelumab-ekko), a drug co-developed by Amgen and AstraZeneca. Starting now, it can be used as a maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in people aged 12 and older. CRSwNP is a long-term sinus condition featuring inflammation and non-cancerous growths called…